| dc.creator | Rigotti R,Attilio | |
| dc.creator | Arteaga Ll,Antonio | |
| dc.creator | Maiz G,Alberto | |
| dc.date | 2006-05-01 | |
| dc.date.accessioned | 2017-03-07T15:38:15Z | |
| dc.date.available | 2017-03-07T15:38:15Z | |
| dc.identifier | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000500014 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/388516 | |
| dc.description | Primary and secondary prevention trials have clearly demonstrated that lowering serum cholesterol levels with statins reduces the incidence of cardiovascular events. Recent studies plus post hoc analysis of previous clinical trials show that risk reduction is proportional to the magnitude of LDL cholesterol lowering. Therefore, new recommendations of the National Cholesterol Education Program (USA) have defined a category of patients with very high cardiovascular risk, who should achieve serum LDL cholesterol levels below 70 mg/dl. This proposal will require new and more efficient pharmacologic strategies to attain the increasingly strict therapeutic goals for LDL cholesterol. This article reviews the clinical studies that support the use of intensive lipid lowering therapy to reduce cardiovascular risk. An effective reduction of serum cholesterol can be obtained using statins in high doses or a combination of hypolipidemic drugs with different mechanisms of action | |
| dc.format | text/html | |
| dc.language | es | |
| dc.publisher | Sociedad Médica de Santiago | |
| dc.source | Revista médica de Chile v.134 n.5 2006 | |
| dc.subject | Hydroxymethylglutaryl-CoA reductase inhibitors | |
| dc.subject | Hypercholesterolemia | |
| dc.title | Terapia hipolepemiante intensiva en el manejo del riesgo cardiovascular ateroesclerótico | |
| dc.type | Artículos de revistas | |
